Carolinas HealthCare System

Research and Clinical Trials

Title  
Envivo-016
Brief Description  
This study is to assess the safety and the efficacy of 2 doses of once daily EVP-6124 tablets (1 and 2 mg) as an adjunctive pro-cognitive treatment, versus placebo, when added to chronic, stable, atypical anti-psychotic therapy in subjects with schizophrenia
Who may be Eligible  
Male or female 18 to 50 with a diagnosis of schizophrenia
Start Date  
08/01/2013
IRB Number  
C-171
Principal Investigator  
Tcheremissine, Oleg
Contact Name  
Dineen

For More Information, Contact   Dineen  Gardner , BA
Phone:  (740) 446-7511  Fax:  (704) 446-7505 
Email:  dgardner@carolinas.org
Address:  465 N. Wendover Road
Charlotte, NC 28211
Close